Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhone Ma Holdings BhdXKLS:5278 62 EV-to-EBIT is 5.65 as of Aug. 20, 2026, which is 46% below its 10-year median of 10.42. GuruFocus rates XKLS:5278 with a GF Score™ of 62/100 and a GF Value™ of RM0.94 (Modestly Undervalued). Among 687 Drug Manufacturers companies, Rhone Ma Holdings Bhd ranks better than 87.34% on this metric.
Rhone Ma Holdings Bhd (XKLS:5278) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Rhone Ma Holdings Bhd's Enterprise Value for the quarter that ended in Mar. 2026 was RM130.7 Mil.
Rhone Ma Holdings Bhd's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM23.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:5278 vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Rhone Ma Holdings Bhd's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhone Ma Holdings Bhd EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rhone Ma Holdings Bhd's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Rhone Ma Holdings Bhd's EV-to-EBIT falls into.
Rhone Ma Holdings Bhd's current Enterprise Value is RM130.3 Mil.
Rhone Ma Holdings Bhd's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was RM23.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhone Ma Holdings Bhd (XKLS:5278) has a EV-to-EBIT of 5.65 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Rhone Ma Holdings Bhd and its competitors. This is 46% below median its historical median of 10.42. According to the industry distribution chart, Rhone Ma Holdings Bhd ranks #87 out of 687 companies in the Drug Manufacturers industry, placing it in the top 12.7%.
Is Rhone Ma Holdings Bhd's EV-to-EBIT too high?
Rhone Ma Holdings Bhd's current EV-to-EBIT of 5.65 is 46% below median its 10-year median of 10.42. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Rhone Ma Holdings Bhd's value of 5.65 is 64.3% below this industry median. Based on the distribution chart, Rhone Ma Holdings Bhd ranks #87 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Rhone Ma Holdings Bhd has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Rhone Ma Holdings Bhd's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rhone Ma Holdings Bhd ranks #87 out of 687 companies for EV-to-EBIT. This places Rhone Ma Holdings Bhd in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.81. Rhone Ma Holdings Bhd's value of 5.65 is 64.3% below this benchmark. While the company's 10-year median is 10.42 vs. the industry median of 15.81, Rhone Ma Holdings Bhd has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhone Ma Holdings Bhd's current EV-to-EBIT of 5.65 is 64.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Rhone Ma Holdings Bhd and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhone Ma Holdings Bhd's current EV-to-EBIT is 5.65, which is 46% below median its own 10-year median of 10.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhone Ma Holdings Bhd stock overvalued right now?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd (XKLS:5278) is currently considered Modestly Undervalued. The stock's GF Value™ is RM0.94, compared to a current price of RM0.68 — trading 27.7% below its estimated fair value. The current EV-to-EBIT is 5.65, which is 46% below median its 10-year median of 10.42 and 64.3% below the Drug Manufacturers industry median of 15.81. Rhone Ma Holdings Bhd's overall GF Score™ is 62/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Rhone Ma Holdings Bhd (XKLS:5278), the current EV-to-EBIT is 5.65 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rhone Ma Holdings Bhd (XKLS:5278) Overvalued in 2026?
Based on GuruFocus' analysis, Rhone Ma Holdings Bhd stock appears to be undervalued.
The current stock price of RM0.68 is trading 27.7% below its estimated GF Value™ of RM0.94.
GuruFocus considers Rhone Ma Holdings Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:5278:
EV-to-EBIT: 5.65 (46% below median its 10-year median of 10.42)
GF Value™: RM0.94 vs. price of RM0.68 (27.7% below fair value)
Industry Position: 64.3% below the Drug Manufacturers median (#87 of 687)
No single metric tells the full story. See the XKLS:5278 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rhone Ma Holdings Bhd, along with its subsidiaries, is mainly involved in the provision of end-to-end animal health solutions. The Group provides veterinary consultation services, diagnostic laboratory analyses, R&D, and is engaged in the manufacturing and distribution of animal health products. Its reportable segments are: Animal health products and equipment, Food ingredients, and Others. The majority of its revenue is generated from the Animal health products and equipment segment, which is engaged in marketing, trading, distribution, and manufacturing of animal health products and equipment, such as pharmaceuticals, vaccines, feed additives, pesticides, and others. Geographically, the Group's operations are predominantly located in Malaysia.
62GF Score
Get the complete analysis for XKLS:5278
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:5278 has been successfully added to your 
